Immunocore Holdings plc (NASDAQ:IMCR) Financial Analysis

• Immunocore's Return on Invested Capital (ROIC) is -1.74% and its Weighted Average Cost of Capital (WACC) is 7.98%, indicating it is not generating returns above its cost of capital.
• Compared to peers, Immunocore has a better ROIC to WACC ratio, suggesting a relatively better potential for capital efficiency improvement.
• All companies in this analysis, including Immunocore, operate with a negative ROIC, typical for early-stage biotechnology firms.

Immunocore Holdings plc (NASDAQ:IMCR) is a biotechnology company focused on developing T cell receptor-based therapeutics. The company is in the development stage, which often involves high research and development (R&D) costs before reaching profitability. This is reflected in its financial metrics, particularly the Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC).

Immunocore's ROIC is -1.74%, while its WACC is 7.98%, resulting in a ROIC to WACC ratio of -0.22. This indicates that the company is not currently generating returns above its cost of capital. This is a common scenario for companies in the biotechnology sector, especially those in the development stage, as they often incur significant R&D expenses before achieving profitability.

When comparing Immunocore to its peers, Vor Biopharma Inc. (VOR) has a ROIC of -232.79% and a WACC of 9.67%, resulting in a ROIC to WACC ratio of -24.09. Cullinan Therapeutics, Inc. (CGEM) has a ROIC of -53.35% and a WACC of 4.55%, with a ROIC to WACC ratio of -11.72. Sana Biotechnology, Inc. (SANA) reports a ROIC of -57.87% and a WACC of 12.06%, leading to a ROIC to WACC ratio of -4.80.

Design Therapeutics, Inc. (DSGN) stands out among the peers with a ROIC of -38.71% and a WACC of 11.33%, resulting in the highest ROIC to WACC ratio of -3.42. Although still negative, this suggests that DSGN is closer to achieving a positive return on its invested capital relative to its cost of capital than its peers. This could indicate a relatively better potential for capital efficiency improvement.

All companies in this analysis, including Immunocore, are currently operating with a negative ROIC, which is typical for early-stage biotechnology firms. Investors should consider these metrics alongside other factors such as pipeline progress, market potential, and financial health when evaluating investment opportunities in the biotechnology sector.